Academic Journal
Study on the structure-activity relationships of natural γ-pyranone products and their derivatives with anti-AD activities focusing on metal chelation.
| Title: | Study on the structure-activity relationships of natural γ-pyranone products and their derivatives with anti-AD activities focusing on metal chelation. |
|---|---|
| Authors: | Mao J; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China., Wang C; Bijie Institute of Traditional Chinese Medicine, Bijie, 551700, China.; Guizhou Key Laboratory for Germplasm Innovation and Resource-Efficient Utilization of Dao-Di Herbs, Guizhou, 550025, China., Li X; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China., Du R; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China., Zhang X; Bijie Institute of Traditional Chinese Medicine, Bijie, 551700, China.; Guizhou Key Laboratory for Germplasm Innovation and Resource-Efficient Utilization of Dao-Di Herbs, Guizhou, 550025, China., Shen R; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. shenr2016@126.com., Yang A; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. yah408@163.com., Kou X; School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. xiaodikou2013@163.com. |
| Source: | Molecular diversity [Mol Divers] 2026 Aug; Vol. 30 (4), pp. 4701-4717. Date of Electronic Publication: 2025 Dec 03. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: ESCOM Science Publishers Country of Publication: Netherlands NLM ID: 9516534 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-501X (Electronic) Linking ISSN: 13811991 NLM ISO Abbreviation: Mol Divers Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Leiden, The Netherlands : ESCOM Science Publishers, c1995- |
| MeSH Terms: | Alzheimer Disease*/drug therapy , Alzheimer Disease*/metabolism , Biological Products*/chemistry , Biological Products*/pharmacology , Biological Products*/therapeutic use , Chelating Agents*/chemistry , Chelating Agents*/pharmacology , Chelating Agents*/therapeutic use , Metals*/chemistry , Pyrones*/chemistry , Pyrones*/pharmacology , Pyrones*/therapeutic use, Structure-Activity Relationship ; Humans ; Animals |
| Abstract: | Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory loss and cognitive impairment. It seriously affects the health and quality of life of the elderly. It has a complex pathogenesis including β-amyloid (Aβ) deposition, Tau protein hyperphosphorylation, cholinergic neurotransmitter deficiency, metal ion dyshomeostasis, and oxidative stress, etc. Despite intensive research, there is still a lack of effective clinical drugs to treat or control AD progression. Natural products and their derivatives exhibit multi-target anti-AD effects, together with low toxicity and affordability, have emerged as promising lead compounds for drug discovery. This review summarizes the studies on anti-AD activities of natural products bearing γ-pyranone structure and their derivatives, and further discusses their structure-activity relationships (SARs), which provided a theoretical basis for the development of effective anti-AD drugs. (© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.) |
| Competing Interests: | Declarations. Conflict of interest: The authors declare no competing interests. |
| References: | Oxid Med Cell Longev. 2018 Jun 14;2018:2856063. (PMID: 30013719) Eur J Med Chem. 2020 Apr 15;192:112180. (PMID: 32131034) Eur J Pharmacol. 2020 Nov 15;887:173554. (PMID: 32941929) Acta Pharm Sin B. 2015 Jan;5(1):67-73. (PMID: 26579427) Mol Divers. 2025 Apr;29(2):1323-1335. (PMID: 38935304) Eur J Pharmacol. 2021 Apr 15;897:173950. (PMID: 33607107) Nat Prod Res. 2012;26(13):1265-70. (PMID: 21985404) Bioorg Med Chem Lett. 2020 Feb 15;30(4):126927. (PMID: 31901382) Curr Neuropharmacol. 2025;23(6):728-754. (PMID: 39665306) Pharmacol Res Perspect. 2025 Aug;13(4):e70131. (PMID: 40531439) J Neurochem. 2007 Nov;103(4):1355-67. (PMID: 17961201) Food Funct. 2024 Apr 22;15(8):4233-4245. (PMID: 38517352) Am J Clin Nutr. 2004 May;79(5):727-47. (PMID: 15113710) J Inorg Biochem. 2023 Feb;239:112086. (PMID: 36495657) Ageing Res Rev. 2025 Jul;109:102772. (PMID: 40389171) Neurochem Res. 2023 Dec;48(12):3485-3511. (PMID: 37578655) J Enzyme Inhib Med Chem. 2022 Dec;37(1):792-816. (PMID: 35193434) Br J Nutr. 2008 May;99 E Suppl 1:ES60-77. (PMID: 18503736) J Neurochem. 2007 Jun;101(6):1596-606. (PMID: 17298385) Bioorg Med Chem. 2015 Feb 15;23(4):668-80. (PMID: 25614117) Handb Clin Neurol. 2019;167:231-255. (PMID: 31753135) Neurol Sci. 2014 Jun;35(6):923-8. (PMID: 24522515) Bioorg Med Chem Lett. 2013 May 1;23(9):2636-41. (PMID: 23511019) Biomol Ther (Seoul). 2023 May 1;31(3):285-297. (PMID: 36646447) Food Chem Toxicol. 1999 Sep-Oct;37(9-10):937-42. (PMID: 10541448) Eur J Med Chem. 2020 Jul 15;198:112257. (PMID: 32375073) Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16568-73. (PMID: 17050681) Mol Neurobiol. 2017 Nov;54(9):7028-7041. (PMID: 27796744) Int J Mol Sci. 2022 Nov 27;23(23):. (PMID: 36499159) Med Oncol. 2025 Jul 13;42(8):328. (PMID: 40652415) Signal Transduct Target Ther. 2025 Mar 05;10(1):74. (PMID: 40038239) Pharmacol Ther. 2024 Dec;264:108731. (PMID: 39426604) Arch Pharm (Weinheim). 2025 Mar;358(3):e2400671. (PMID: 40059628) Med Sci Monit. 2021 Jul 26;27:e934077. (PMID: 34305135) Brain Behav. 2021 May;11(5):e02100. (PMID: 33704934) Eur J Med Chem. 2015 Apr 13;94:348-66. (PMID: 25778991) FEBS J. 2017 Apr;284(7):1040-1044. (PMID: 28054745) Curr Med Chem. 2022;29(10):1757-1803. (PMID: 33982650) Bioorg Chem. 2025 Aug;163:108666. (PMID: 40513452) Eur J Clin Pharmacol. 2022 Oct;78(10):1567-1587. (PMID: 35881170) Proc Nutr Soc. 2010 May;69(2):244-60. (PMID: 20158941) Eur J Pharmacol. 2005 Apr 18;513(1-2):47-55. (PMID: 15878708) Alzheimers Res Ther. 2022 Nov 4;14(1):164. (PMID: 36329553) Molecules. 2021 Sep 14;26(18):. (PMID: 34577044) Int J Neurosci. 2025 Jul;135(7):797-806. (PMID: 39136404) Curr Alzheimer Res. 2014;11(9):869-81. (PMID: 25274114) Nutrients. 2019 Nov 04;11(11):. (PMID: 31689947) Ageing Res Rev. 2025 Jan;103:102595. (PMID: 39581354) Eur J Med Chem. 2014 Apr 9;76:314-31. (PMID: 24589487) Curr Issues Mol Biol. 2025 Aug 08;47(8):. (PMID: 40864789) Eur J Epidemiol. 2000 Apr;16(4):357-63. (PMID: 10959944) Pharmacol Res. 2005 May;51(5):427-35. (PMID: 15749457) Chem Biol Drug Des. 2019 Feb;93(2):188-200. (PMID: 30299583) Planta Med. 2008 Nov;74(14):1667-77. (PMID: 18937165) J Alzheimers Dis. 2011;24(1):85-100. (PMID: 21297270) J Am Geriatr Soc. 1996 Jul;44(7):865-70. (PMID: 8675940) Neurochem Res. 2016 Jul;41(7):1806-17. (PMID: 27038926) Neuroscience. 2006;138(3):1031-9. (PMID: 16310963) J Biol Chem. 2003 Sep 12;278(37):34783-93. (PMID: 12826665) Eur J Med Chem. 2020 Feb 1;187:111958. (PMID: 31865014) Bioorg Med Chem Lett. 2021 Oct 1;49:128316. (PMID: 34391893) Neurochem Int. 2008 Mar-Apr;52(4-5):878-86. (PMID: 18037535) Eur J Med Chem. 2021 Mar 5;213:113154. (PMID: 33476932) Lancet Neurol. 2003 Sep;2(9):539-47. (PMID: 12941576) Biochem J. 2001 Sep 15;358(Pt 3):547-57. (PMID: 11535118) Front Chem. 2022 May 11;10:842208. (PMID: 35646819) Front Pharmacol. 2022 Aug 29;13:903099. (PMID: 36105221) Eur J Med Chem. 2022 Apr 5;233:114216. (PMID: 35227980) Interdiscip Toxicol. 2009 Dec;2(4):211-8. (PMID: 21217857) Chem Biol Interact. 2022 Nov 1;367:110173. (PMID: 36152810) Chem Biol Drug Des. 2024 Apr;103(4):e14529. (PMID: 38670598) Int J Mol Sci. 2022 Dec 21;24(1):. (PMID: 36613544) Phytomedicine. 2014 Sep 25;21(11):1303-9. (PMID: 25172794) Biomed Pharmacother. 2021 May;137:111253. (PMID: 33545661) CNS Neurol Disord Drug Targets. 2025;24(9):685-700. (PMID: 40114567) Mini Rev Med Chem. 2021;21(20):3219-3248. (PMID: 33663363) J Alzheimers Dis. 2024;99(s1):S5-S22. (PMID: 38339930) J Mol Biol. 2019 Apr 19;431(9):1843-1868. (PMID: 30664867) Inflamm Res. 2019 Jun;68(6):471-479. (PMID: 30927050) Mini Rev Med Chem. 2009 Jan;9(1):31-59. (PMID: 19149659) Bioorg Med Chem. 2021 Sep 15;46:116385. (PMID: 34481338) Bioorg Chem. 2021 Feb;107:104602. (PMID: 33453647) J Alzheimers Dis. 2024;101(s1):S275-S283. (PMID: 39422955) Mol Psychiatry. 2025 Jan;30(1):272-284. (PMID: 39232196) Eur J Pharm Sci. 2021 Nov 1;166:105976. (PMID: 34419572) Free Radic Biol Med. 2012 Jan 1;52(1):35-45. (PMID: 21982844) Int J Mol Sci. 2021 Nov 18;22(22):. (PMID: 34830326) Neural Regen Res. 2023 Dec;18(12):2582-2591. (PMID: 37449593) Phytother Res. 2021 Feb;35(2):810-822. (PMID: 32961631) CNS Neurosci Ther. 2017 Jun;23(6):526-534. (PMID: 28429536) Bioorg Med Chem. 2017 Mar 15;25(6):1997-2009. (PMID: 28237559) Biofactors. 2025 Sep-Oct;51(5):e70047. (PMID: 40899340) Brain Res. 2013 Jan 25;1492:33-45. (PMID: 23178511) Commun Biol. 2024 Jul 28;7(1):912. (PMID: 39069528) Am J Epidemiol. 2007 Jun 15;165(12):1364-71. (PMID: 17369607) Neuroscience. 2020 Jul 1;438:198-214. (PMID: 32335218) Chem Rev. 2019 Jan 23;119(2):1221-1322. (PMID: 30095897) Biochem Soc Trans. 2008 Dec;36(Pt 6):1282-7. (PMID: 19021541) Cell Mol Neurobiol. 2016 Jul;36(5):811-20. (PMID: 27002719) Chem Biodivers. 2020 Oct;17(10):e2000442. (PMID: 32692899) |
| Contributed Indexing: | Keywords: Alzheimer’s disease; Metal chelation; Natural products; γ-Pyranone |
| Substance Nomenclature: | 0 (Biological Products) 0 (Chelating Agents) 0 (Metals) 0 (Pyrones) |
| Entry Date(s): | Date Created: 20251203 Date Completed: 20260704 Latest Revision: 20261010 |
| Update Code: | 20261010 |
| DOI: | 10.1007/s11030-025-11417-x |
| PMID: | 41335180 |
| Database: | MEDLINE |
Be the first to leave a comment!